TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05563415

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medicare AWV Practice Redesign Toolkit
Description: Electronic health record-based tools coupled with practice redesign strategies and approaches
Study: NCT04682158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3 Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3 Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3 Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study: NCT06198179

Intervention type: OTHER
Group type: OTHER
Intervention: upper limb children action-observation training (UPCAT)
Description: upper limb children action-observation training (UPCAT) without visual Feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper limb children action-observation training (UP-CAT) with visual feedback
Description: upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
Study: NCT06044142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Low level laser therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser
Description: Low level laser therapy
Study: NCT06129851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study: NCT05138458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-101
Description: CD5 ATAK cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Description: IV administration of fludarabine and cyclophosphamide
Study: NCT06457659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Rehab Group
Description: The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO_QOL.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Rehab Group
Description: The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
Study: NCT06253195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally.
Study: NCT04359394

Intervention type: OTHER
Intervention: biological sampling
Description: In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.
Study: NCT06608485

Intervention type: DEVICE
Intervention: HARMONIC 700 Shears
Description: There is no intervention, beyond necessary clinical care, in this study. HARMONIC 700 Shears for vessel transection were used according to instructions for use.
Study: NCT04359394

Intervention type: OTHER
Intervention: Phenotypic description
Description: Phenotypic characterization of the patient's clinical features
Study: NCT06593275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protection of the palatal donor area with flowable resin
Description: Use of fluid resin for protection of the palatal donor area to assess postoperative pain generated during14 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protection of the palatal donor area with a self-adhesive dressing
Description: Use of a self-adhesive dressing for protection of the palatal donor area to evaluate postoperative pain generated for 14 days
Study: NCT06614582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Supporting Nasopharyngeal Airway (ssNPA)
Description: The ssNPA device is a flexible, medical-grade silicone, nasal tube that is self-inserted into the airway through one nostril and worn during the night. It can also be used during the day. The device works by supporting collapsed airway muscles and keeping the airway open.~In addition to wearing the device, study team members will call monthly and collect certain data, and medical information and participants will be asked to have a sleep study at the 12-month visit.
Study: NCT04856384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronisation abilities
Description: The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
Study: NCT04359394

Intervention type: OTHER
Intervention: Photography
Description: All affected areas will be photographed at each visit with 2-dimensional standardized photography
Study: NCT05129774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery with PALND
Description: sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery without PALND
Description: surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
Study: NCT04583735

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TEPEZZA
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT05775718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Recombinant
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Recombinant
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Recombinant
Description: Injection
Study: NCT06702774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Active case finding
Description: Villagers will be informed through public announcements and social workers. Before the campaign, social workers and village doctors will recruit participants and obtain consent through door-to-door visits. A mobile van equipped with an AI-assisted digital radiography (DR) machine and a refrigerator will visit villages on agreed dates. Participants will complete a TB symptom questionnaire and undergo DR screening. Those with TB symptoms or abnormal DR results will provide on-site sputum samples and collect additional morning and night samples. Trained staff will ensure proper collection and offer nebulizer support if needed. Samples will be transported daily to hospitals for testing using smear, culture, and GeneXpert. Participants with negative bacteriological results but abnormal findings will be referred for further clinical assessment.
Study: NCT06721299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: Beta-Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: Beta-Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: Beta-Agonist
Study: NCT06721728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral health educational program
Description: Flyer distributed on the children with data about oral hygiene measures as well as diet advice related to their condition, in addition to modeling the correct tooth brushing habits using a cast and tooth brush.
Study: NCT06721130

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG radiotracer
Description: Pilot study evaluating the role of FDG PET/CT in Cavernous sinus syndrome
Study: NCT06720142

Intervention type: DEVICE
Intervention: Mg OSTEOCRETE as a bone void filler
Description: Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by bone tumor resection

Intervention type: DEVICE
Intervention: Mg OSTEOCRETE as a bone void filler
Description: Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by aseptic loosening of orthopaedic hardware

Intervention type: DEVICE
Intervention: Mg OSTEOCRETE as a bone void filler
Description: Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by trauma-related conditions
Study: NCT06001593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YPS-201b
Description: electrical stimulation device.
Study: NCT05523050

Intervention type: PROCEDURE
Group type: OTHER
Intervention: active surgical intervention
Description: two kinds: one is colostomy, and the other one is colonic exclusion
Study: NCT05001204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RM26
Description: 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
Study: NCT06467916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
Study: NCT06001593

Intervention type: DRUG
Group type: OTHER
Intervention: betahistine
Description: Relieve symptoms of balance disorders or dizziness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine
Description: Relieve symptoms of balance disorders or dizziness

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: betahistine
Description: Relieve symptoms of balance disorders or dizziness

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: YPS-201b
Description: sham electrical stimulation device.
Study: NCT06237465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
Study: NCT05031559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Training
Description: Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
Study: NCT05835154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Complete checklist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo semi-structured feedback interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT06415188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game with headset
Description: Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
Study: NCT06546995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-323511
Description: Participants will receive NMRA-323511 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-323511
Description: Participants will receive NMRA-323511 orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets orally.
Study: NCT06190860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Leukocyte and platelet-rich fibrin
Description: Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.

Intervention type: OTHER
Group type: OTHER
Intervention: Intraoral Scan
Description: Intraoral scan will be taken in the treated zone after tooth extraction and after four months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoral Scan
Description: Intraoral scan will be taken in the treated zone after tooth extraction and after four months.

Intervention type: RADIATION
Group type: OTHER
Intervention: Computed Tomography
Description: Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
Study: NCT04575909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aprosodia Intervention
Description: Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aprosodia Intervention
Description: Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aprosodia Intervention
Description: Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aprosodia Intervention
Description: Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No-Intervention
Description: Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
Study: NCT05877508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER002
Description: Intravenous infusion of AER002

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT04517604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magventure MagProx100 with MagOption
Description: iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B60 Butterfly coils). Only the active setting will be used.A MagVenture C-B60 coil will be used to deliver single pulse TMS to the non-dominant MC to identify the ab-ductor pollicis brevis (APB) muscle coordinates. The integrated Localite neuronavigation system will be used.
Study: NCT05966896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implanted epidural stimulator
Description: implantable multi-programmable neurostimulation system to deliver electrical stimulation to neural targets in the spinal cord
Study: NCT05908903

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Drinks with active ingredients such as poria and GABA
Description: Take drinks half an hour before bedtime, 10ml/bag/day, daily. Subjects are uniformly using skin care products provided by the sponsor during the test.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drinks with active ingredients such as poria and GABA
Description: Take drinks half an hour before bedtime, 10ml/bag/day, daily. Subjects are uniformly using skin care products provided by the sponsor during the test.